$0.00
0.00%
Nasdaq, Wed, Sep 03 2025
ISIN
US4976341051
Symbol
KRBP

Kiromic BioPharma Inc Stock price

$0.00
+0.00 0.00% 1M
-1.50 99.73% 6M
-0.90 99.56% YTD
-1.93 99.79% 1Y
-12.02 99.97% 3Y
-360.00 100.00% 5Y
-360.00 100.00% 10Y
-360.00 100.00% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.00 0.00%
ISIN
US4976341051
Symbol
KRBP
Industry

Key metrics

Basic
Market capitalization
$10.0k
Enterprise Value
$12.5m
Net debt
$12.5m
Cash
$1.1m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.0
Financial Health
Equity Ratio
-147.3%
Return on Equity
268.0%
ROCE
192.5%
ROIC
-
Debt/Equity
-1.1
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-21.5m | -
EBIT
$-23.8m | -
Net Income
$-33.7m | -
Free Cash Flow
$-19.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-21.6% | -
EBIT
-19.2% | -
Net Income
-43.5% | -
Free Cash Flow
7.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-21.8
FCF per Share
$-13.0
Short interest
6.8%
Employees
44
Rev per Employee
$0.0
Show more

Is Kiromic BioPharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Financial data from Kiromic BioPharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.33 9.33
13% 13%
-
- Research and Development Expense 14 14
56% 56%
-
-22 -22
22% 22%
-
- Depreciation and Amortization 2.23 2.23
0% 0%
-
EBIT (Operating Income) EBIT -24 -24
19% 19%
-
Net Profit -34 -34
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kiromic BioPharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. Its technologies include Intelligent Immunotherapy, Diamond AI, CancerSplice, ABBIE, and CAR-T Proprietary Binder Technology. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.

Head office United States
CEO Pietro Bersani
Employees 44
Founded 2006
Website kiromic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today